11:30:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-06-18 Bokslutskommuniké 2024
2024-03-13 Kvartalsrapport 2024-Q3
2023-12-12 Kvartalsrapport 2024-Q2
2023-10-18 Ordinarie utdelning SDOS 0.00 SEK
2023-10-17 Årsstämma 2024
2023-09-13 Kvartalsrapport 2024-Q1
2023-06-15 Bokslutskommuniké 2023
2023-03-08 Kvartalsrapport 2023-Q3
2022-12-07 Kvartalsrapport 2023-Q2
2022-10-18 Ordinarie utdelning SDOS 0.00 SEK
2022-10-17 Årsstämma 2023
2022-09-13 Kvartalsrapport 2023-Q1
2022-06-28 Bokslutskommuniké 2022
2022-03-11 Kvartalsrapport 2022-Q3
2021-12-14 Kvartalsrapport 2022-Q2
2021-10-21 Ordinarie utdelning SDOS 0.00 SEK
2021-10-20 Årsstämma 2022
2021-09-23 Kvartalsrapport 2022-Q1
2021-06-29 Bokslutskommuniké 2021
2021-03-10 Kvartalsrapport 2021-Q3
2020-12-16 Kvartalsrapport 2021-Q2
2020-10-07 Ordinarie utdelning SDOS 0.00 SEK
2020-10-06 Årsstämma 2021
2020-09-25 Kvartalsrapport 2021-Q1
2020-06-26 Bokslutskommuniké 2020
2020-03-10 Kvartalsrapport 2020-Q3
2019-12-18 Kvartalsrapport 2020-Q2
2019-10-09 Ordinarie utdelning SDOS 0.00 SEK
2019-10-08 Årsstämma 2020
2019-09-12 Kvartalsrapport 2020-Q1
2019-06-28 Bokslutskommuniké 2019
2018-12-14 Kvartalsrapport 2019-Q2
2018-10-03 Ordinarie utdelning SDOS 0.00 SEK
2018-10-02 Årsstämma 2019
2018-06-28 Bokslutskommuniké 2018
2018-03-22 Kvartalsrapport 2018-Q3
2017-12-15 Kvartalsrapport 2018-Q2
2017-10-03 Ordinarie utdelning SDOS 0.00 SEK
2017-10-02 Årsstämma 2018
2017-09-29 Kvartalsrapport 2018-Q1
2017-06-28 Bokslutskommuniké 2017
2017-03-22 Kvartalsrapport 2017-Q3
2016-12-15 Kvartalsrapport 2017-Q2
2016-09-21 Ordinarie utdelning SDOS 0.00 SEK
2016-09-20 Kvartalsrapport 2017-Q1
2016-09-20 Årsstämma 2017
2016-06-30 Bokslutskommuniké 2016
2016-03-15 Kvartalsrapport 2016-Q3
2015-12-11 Kvartalsrapport 2016-Q2
2015-09-24 Ordinarie utdelning SDOS 0.00 SEK
2015-09-23 Årsstämma 2016
2015-09-23 Kvartalsrapport 2016-Q1
2015-06-23 Bokslutskommuniké 2015
2015-03-26 Kvartalsrapport 2015-Q3
2014-12-19 Kvartalsrapport 2015-Q2
2014-10-14 Årsstämma 2015
2014-09-24 Ordinarie utdelning SDOS 0.00 SEK
2014-09-23 Kvartalsrapport 2015-Q1
2014-06-13 Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandidos är verksamt inom medicinteknik. Bolaget erbjuder produkter och system för kvalitetssäkring av avancerad strålterapi mot cancer. Systemen analyserar stråldosen inför och under pågående strålbehandling. Bolaget grundades under 2002 och den första produkten lanserades 2006. Sedan starten har Scandidos levererat produkter till strålterapikliniker på global nivå. Huvudkontoret ligger i Uppsala.
2022-02-25 08:50:00

Delta4 Insight provides radiotherapy clinics with an independent QA solution that verifies the accuracy and quality of their treatment plans. Featuring a state-of -the art Monte Carlo dose engine, enabling exceptional calculation accuracy, giving the clinic full confidence that the planned treatments fulfil the prescription for each specific patient. Delta4 Insight extends the Delta4 family of products into a full end-to end verification solution.

Delta4 Insight - Golden standard secondary dose calculation
Delta4 Insight is an independent secondary 3D dose calculation software that utilizes a Monte Carlo engine to verify the calculations of a clinic’s Treatment Planning System (TPS). It provides the user with an independent verification of the dose calculation algorithm and verifies that the calculations the TPS makes are accurate.

Delta4 Insight completes the ScandiDos patient QA product portfolio which now covers patient QA from prescription to final fraction. Not only can Delta4 users expect to increase the workflow efficiency but, most importantly, they can also carry out their work with full confidence that throughout the whole treatment process the dose delivered to patients are safe.

”Our ambition when developing Delta4 Insight was to extend our Delta4 family of products into a full end-to-end verification solution where the customer can be confident that Delta4 provides the true values and not just the deviations”, says Görgen Nilsson, CTO and founder.

Delta4 Insight will initially be available in most of Europe and key markets in Asia, but further markets will be addressed based on regulatory approvals. Primary target groups are current Delta4 Phantom+ customers, today over 800 clinics, and radiotherapy clinics buying the Delta4 Phantom+.

” I am very pleased that we are now bringing Delta4 Insight to market. Together with ScandiDos’ existing products Delta4 Phantom+ and Delta4 Discover, Delta4 Insight will offer independent and complete verifications of all treatment steps from prescription to final treatment fraction”, says Gustaf Piehl, President & CEO.

Learn more about Delta4 Insight